Non-Small Cell Lung Cancer Stage IIIA Clinical Trial
Official title:
Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC: a Multicenter, Open-label, Phase II Randomized Controlled Trial
This is a multicenter, randomized, controlled, phase II study assessing the efficacy and safety of Almonertinib compared Erlotinib or platinum doublet chemotherapy (carboplatin or cisplatin + pemetrexed) as neoadjuvant therapy to EGFRm+ IIIA-N2 NSCLC patients.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02977169 -
To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT02974426 -
To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
|
Phase 3 | |
| Completed |
NCT01991418 -
Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC)
|
N/A | |
| Recruiting |
NCT01410214 -
Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations
|
Phase 2 | |
| Recruiting |
NCT05732974 -
A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse
|
||
| Recruiting |
NCT01926483 -
Phase II Trial of Regimen for Stage III (N2) NSCLC Using Induction Treatment Followed by Resection
|
Phase 2 | |
| Recruiting |
NCT04716946 -
Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy
|
Phase 2 | |
| Recruiting |
NCT06268613 -
A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy
|
Phase 1 |